Sarepta and the RNAi Pivot
How one deal is reshaping two companies’ futures
This piece was developed using Primary Source AI (PSAI), drawing directly from Sarepta and Arrowhead filings, transcripts, and related source material.
Sarepta Therapeutics has long been defined by its work in Duchenne muscular dystrophy (DMD) and gene therapy. But late 2024 marked a turning point. On November 25, 2024, the company signed a sweeping licensing and collaboration agreement with Arrowhead Pharmaceuticals, which became effective February 7, 2025.
The deal’s scale was striking: $500 million in cash, plus a $325 million equity investment (11.9 million shares of Arrowhead stock). The framework went further — annual fees of up to $250 million over five years, as much as $300 million in near-term enrollment payments, and up to $10.3 billion in potential milestones. Tiered royalties up to the low double digits would follow if products reach market. By mid-2025, Arrowhead had already earned a $100 million milestone for the DM1 program.
The financial terms were matched by a substantial portfolio transfer. Sarepta gained exclusive global rights to four clinical-stage assets, three preclinical programs, and a discovery collaboration covering up to six additional targets.
Clinical-stage programs:
SRP-1001 (FSHD1): Phase 1/2; cohorts 1–3 in Part 1 enrolled. Proof-of-biology readout expected 2025.
SRP-1003 (DM1): Phase 1/2; early cohorts enrolled, with authorization to escalate. $100M milestone paid July 2025. Another $200M possible as enrollment progresses. Preliminary data expected 2025.
SRP-1002 (IPF): Phase 1/2 for idiopathic pulmonary fibrosis. Expands Sarepta into pulmonary disease.
SRP-1004 (SCA2): Phase 1; Cohort 1 enrolled, safety data expected 2025.
Preclinical programs:
ARO-ATXN1 (SCA1): CTA-ready expected 2026.
ARO-ATXN3 (SCA3): CTA-ready expected 2026.
ARO-HTT (Huntington’s, SRP-1005): CTA filing planned end-2025, Phase 1 start in 1H 2026.
Discovery programs:
Sarepta may select up to six new CNS, skeletal muscle, or cardiac targets.
Arrowhead conducts discovery and preclinical work to deliver CTA-ready packages. Sarepta then assumes clinical development and commercialization.
No near-term milestones are tied to the discovery phase itself.
This portfolio deepens Sarepta’s early pipeline, complements its neuromuscular base, and pushes the company into CNS, pulmonary, and cardiac disease.
Those ambitions took sharper shape on July 16, 2025, when Sarepta announced a major restructuring and pipeline reprioritization. Management framed the move as concentrating resources on “high-value, high-impact programs,” while securing financial flexibility to meet 2027 obligations.
Key elements included:
Refocusing the pipeline on near- and mid-term siRNA opportunities.
Pausing most LGMD gene therapy programs (except SRP-9003, still expected to file a BLA in 2025).
A 36% workforce reduction (~500 employees), expected to save $120M annually from 2026.
Pipeline reprioritization expected to save another ~$300M annually.
Combined ~$400M in yearly savings, strengthening cash flow and supporting repayment of $1.15B in 2027 convertible notes.
As of March 31, 2025, Sarepta held $647.5M in cash and investments. The fair value of its convertible notes had already declined from $1.07B (March) to $849.6M (June).
The Arrowhead partnership and subsequent restructuring mark a clear pivot for Sarepta — away from a gene-therapy-heavy portfolio and toward a future built on chronic, scalable RNAi medicines. The move broadens Sarepta’s reach into CNS and pulmonary disease, while also sharpening its financial discipline.
It is both a scientific expansion and a strategic bet: that RNAi can deliver not only rare-disease breakthroughs, but durable growth engines for the decade ahead. For Sarepta, it marks a pivot in strategy; for Arrowhead, it validates a model where its siRNA pipeline can reshape not just its own trajectory, but the future of its partners.
Not investment advice. Do your own due diligence.